AiMedics' principal research and development focus is the HypoMon® instrument system. The HypoMon® system is a monitoring device used to non-invasively detect the onset of hypoglycaemia in Type I and insulin-dependant Type II diabetics. The system will detect low blood glucose levels (BGL) below 2.5 mmol/l (45 mg/dl) and provide an alarm system for the patient and/or carer to prevent onset of hypoglycaemia complications. HypoMon® will also aid in maintaining tight glycaemic control for the patient, thus improving their glycohaemoglobin, or HbA1c levels.
AiMedics understands the need for the continuous, tight monitoring of BGL and HbA1c levels, particularly overnight, in order to prevent major complications, such as cardiovascular failure, nephropathy, retinopathy and neuropathy. As a result, the scientists and engineers of AiMedics are incorporating the latest break-through technology within the HypoMon® device to provide the continuous monitoring of hypoglycaemia. This technology embeds multi-disciplinary fields, including microelectronics, wireless technology, biomedical and bio-sensor engineering, real-time embeddedoperating system (RTOS) computing and artificial intelligence algorithms.

The HypoMon® mainly consists of a battery powered chest-belt unit worn by the patient (housing a set of four skin surface bio-sensor electrodes) and a hand-held receiver computer. The chest belt digitises, encrypts and transmits the measured parameters to the receiver unit using a wireless communication link. The collected data is applied to a detection algorithm, embedded within the receiver computer, to analyse and determine the critical stage of hypoglycaemia. There is an alarm system that can be activated in case of severe hypoglycaemia, to warn the patient or physician in critical situations.

The diagrams show the HypoMon® system. The top diagram shows the clinical study version used to conduct the trials, the second diagram shows the commercial version, and the third diagram shows the device worn by a patient. The last diagram shows the HypoMonView program used to simulate test results from the HypoMon®.

Development of the HypoMon® is currently being undertaken to seek regulatory body approval for large-scale clinical data collection.
HypoMon's intellectual property is legally protected and bound by Australian and international patent treaties.